Related Experiment Videos
Somatostatin receptors: from basic science to clinical approach--thyroid.
M C Zatelli1, E C degli Uberti
1Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy.
Summary
Somatostatin analogs show limited success in thyroid cancer treatment. However, specific agonists targeting somatostatin receptor 1 show promise in inhibiting medullary thyroid carcinoma cell growth and reducing symptoms.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Somatostatin and its receptors are present in the thyroid gland, but their role in thyroid neoplasia diagnosis and treatment remains controversial.
- Current somatostatin analogs yield conflicting results in managing thyroid cancers, impacting diagnosis, treatment efficacy, and patient outcomes.
Purpose of the Study:
- To investigate the effects of somatostatin receptor (SSTR) agonists on medullary thyroid carcinoma (MTC) cell proliferation and calcitonin secretion.
- To explore the potential antagonism between SSTR2 and SSTR5 agonists and the role of SSTR1 agonists in MTC.
Main Methods:
- Utilized the human medullary thyroid carcinoma cell line (TT) to study the effects of various SSTR agonists.
- Assessed cell proliferation, calcitonin secretion, and calcitonin gene expression in response to selective SSTR agonists.
Main Results:
- SSTR2 activation by agonists inhibited TT cell proliferation, an effect potentially antagonized by SSTR5 agonists.
- SSTR2 and SSTR5 agonists did not affect calcitonin secretion or gene expression.
- SSTR1 agonists demonstrated inhibitory effects on proliferation, calcitonin secretion, and gene expression in parafollicular C cells.
Conclusions:
- Somatostatin receptor 2 agonists show potential for inhibiting MTC cell proliferation, with possible interactions with SSTR5.
- Somatostatin receptor 1 agonists present a promising therapeutic strategy for controlling MTC neoplastic growth and alleviating clinical symptoms by targeting parafollicular C cells.